

Index

- A2K movement *see under* knowledge
Abbott, F.M. 55
abbreviated new drug application (ANDA)
116–18
abuse
dominant position, of 188–9, 198, 307, 364
exclusive rights, of 192, 363
rights, of, 105–6, 165
access
benefit sharing, and *see under* benefit sharing
knowledge (A2K), to *see under* knowledge
medicines and essential medicines *see under*
medicines and drugs
HIV/AIDS drugs *see under* medicines and
drugs
technology, to *see under* technology
Access and Community Rights (2004),
Pakistan Draft Law on 244
Access to Learning Materials Project 309–10
Addor, F. 279, 281, 282
administration of IP laws and offices 21, 23–4
advertising
IGOs, and 274
medicines and drugs, and *see under*
medicines and drugs
misleading 261
regulations, and 365–6
Advisory Committee on Intellectual Property
Rights for Trade Policy Matters (IFAC-3)
141
Affordable Prescription Drugs and Medical
Inventions Act (HR 1708) 108
Africa 51, 129, 148, 223, 224, 315
eastern and southern
education and access to knowledge,
southern Africa in *see under* southern
Africa
genetic resources *see under* genetic
resources
GURTs, and *see under* genetic use
restriction technologies (GURTs)
informal economy in knowledge goods
313–19
sub-Saharan *see* sub-Saharan African
countries
see also developing countries
African, Caribbean and Pacific (ACP)
countries 398, 399, 401
African Intellectual Property Organisation
(OAPI) 31
African Model Law for the Recognition
and Protection of Rights of Local
Communities 223
African Regional Intellectual Property
Organization (ARIPO) 212
Agreement on Trade-Related Aspects of
Intellectual Property Rights *see* TRIPS
agricultural chemical products 5, 98, 273, 371
test data, and 7, 10–11, 15, 370
see also model law for protection of
undisclosed data
agriculture 140, 228, 235–6
Asia 241–2, 281
biotechnology 218
China 42, 242
developing countries 140, 218
EPAs 397
hybrid-based 222
innovation funds 357
IP, and 22, 26, 60, 248
GURTs, and 209, 213, 219, 226, 231
ITPGRFA 240–41
material transfer agreements 257–8
organic 259
precision 214
research and innovation 221, 257, 349, 350,
357
SACU, and 322
Thailand 140, 248
traditional knowledge, and *see under*
traditional knowledge
see also innovation and public research in
Central America
Agricultural Research in Eastern and Central
Africa (ASARECA) 212
agri-food processing 281
agro-biodiversity *see under* biodiversity
agrochemical products *see under* agricultural
chemical products
agro-forestry 241
Alarcon, E. 355
Algeria 56, 57

- Almost Ideal Demand System* (Deaton and Muellbauer) 81–2
- alternative technological protection measures 46
- Andean Community of Nations Decision 279
- Anderfelt, U. 156
- anticircumvention provisions 12–14, 312, 313
- anticommons tragedy 246, 247
- anticompetitive behaviour and concerns 176, 186, 188, 364–5, 367
- South Africa, in *see under* South Africa
- antiretroviral drugs (ARV) and therapy (ART) *see* ARV *under* HIV/AIDS
- sub-Saharan countries, and *see under* sub-Saharan African countries
- antitrust law and policy 163, 364
- approvals *see* marketing approvals
- Arab countries 51–65
- copyright 55, 56, 58, 61
- development-orientated IP policies 59–64
- checks and balances 61
- civil society and consumer groups, involvement of 63–4
- FTAs, dealing with 64
- innovation, creativity and knowledge access, promoting 60–61
- integrated IP policy-making, promoting 61–2
- IP contentious, recognising 59–60
- IP standard setting, participation in 62–3
- tailoring IP regimes to circumstances 60
- general developments at institutional level 51–3
- increasing complexity of international standard-setting 52–3
- proliferation of forums and processes in IP standard-setting 51–2
- general developments at substantial level 53–5
- need to integrate development dimension in IP 53–4
- TRIPS Plus trend 54–5
- IP protection developments 55–64
- association agreements with EU and ENP 56–7, 58
- free trade and investment agreements with US 57–9
- FTAs 56, 63, 64
- EFTA, with 57, 58
- TRIPS agreements, adjusting to 55–6, 57, 58–9, 64
- TRIPS Plus obligations 56, 57, 58–9, 63, 64
- patents 55, 58, 59, 61
- trademarks 55, 58, 61
- Arab-South American Summit 54
- Arfini, F. 294–5
- Argentina xxii, 73, 147, 162, 158, 283
- Armenia 57
- ARV drugs *see* antiretroviral (ARV)
- Asia 30, 51, 61, 123, 368
- IGOs, and *see under* indications of geographical origins (IGOs) and GIs
- Southeast *see* Southeast Asia
- sui generis systems, and *see* sui generis systems of plant variety protection
- Asia-Pacific Economic Co-operation (APEC) 141
- Aspen-Pharmacare 177–8, 182, 201
- Association for Strengthening Agricultural Research in Eastern and Central Africa 212
- Association of South-East Asian Nations (ASEAN) 30, 124, 235
- Australia 253, 259, 276, 283, 292, 312, 366
- Azerbaijan 57
- Bahrain 59, 63, 379
- Ballance, R. 113–14
- Bangladesh 240, 242, 244, 261
- Bangs, R.B. 157
- Barcelona process 56
- Barton, J.H. 258
- Basmati 247, 284, 285, 289
- Bay, Van 291
- Bayer AG 120, 122
- Bayh-Dole Law (1980) 344
- Belarus 57
- Belgium 147
- Bellagio Dialogue xxii–iii
- benefit sharing 243, 245, 251, 258, 264, 266
- access, and (ABS) 236–7, 252–5
- international regime 245
- multilateral system *see under* ITPGRFA
- traditional knowledge *see under* traditional knowledge
- ASEAN Agreement 235
- Bonn Guidelines 239
- GURTs, and 229–30
- traditional knowledge 261
- Berard, L. 277
- Beresford, L. 279
- Bergsten, C.F. 38
- Berne Appendix 320, 322
- Berne Convention 28, 37, 311, 320–21, 324, 331
- Bhutan 240
- Bibile, S. 158
- bilateral agreements 47, 140–42, 235, 311, 366, 368, 390, 396–7
- enforcement, and 390, 396, 397

- FTAs *see* FTAs
 GIs, and 282, 292–3, 296
 investment treaties (BITs) 52, 54, 58
 biodiversity 52, 255
 agro-biodiversity 209, 214, 220, 221, 226–7, 235, 241, 255
 Central America *see under* innovation and public research in Central America
 sui generis regimes 224, 225, 228, 239, 241, 253
 collecting regulations 230
 Convention on *see* Convention on Biological Diversity (CBD)
 IP and, consumer groups discussing 63
 management 142, 252, 263
 medicines, and 257
 protection 61, 229, 253
 TRIPS, and 51, 53
 Biodiversity and Community Knowledge
 Protection Act of Bangladesh (Draft 1998) 244
 Biodiversity Management Committee (BMC) 252, 263
 bioeconomy 342
 Biological Diversity Conservation Act and Bill *see under* Indian
 biological resources 239, 250, 252–3, 255, 257, 265–6, 342, 355, 358
 genetic use restriction technologies, and 217, 223, 227–8, 230
 biopiracy 213, 242, 246, 262, 263
see also piracy and counterfeiting
 bioprospecting 242, 254, 264
 biotechnological innovations 211–12, 235, 237
 biotechnology 15, 42–3, 120, 126, 141, 342, 350
 GURTs, and 211–15, 217–18, 222
 Biotechnology Industry Organization 141
 Blakeney, M. 275, 277, 279
Bleu de Bresse case 279–81
 Board of Investment (BOI) 156
 Boehringer Ingelheim 176, 177, 179, 186, 190–93, 194
 Bolar exemption 109–11, 182
 Bolivia 35
 Bonn Guidelines 239, 250, 255–7, 265
 books *see under* education and access to knowledge *under* southern Africa
 borders and control measures 23, 225, 390, 392, 393–4
 Botswana 200, 305, 328
 copyright regime 322, 323, 326, 328–30, 335, 336, 337
 brand loyalty 88, 152, 153, 166
 branded drugs *see under* generic drugs
 Brasilia Declaration 53–4
 Brazil xxii
 competition laws 366
 compulsory licences *see under* compulsory licences and licensing
 drug production and supply 130, 169
 ARV treatment 128, 132
 emerging economy 397
 IP decision making 23, 24
 coordination of enforcement efforts 26–7
 interministerial coordination 24–5
 public consultations 27
 National Industrial Property Institute (INPI) 24, 25
 pharmaceuticals production 147, 162
 utility model protection 44
 Brazilian Institute for Agriculture Research (EMBRAPA) 345
 breeders
 exceptions 228
 rights 212, 214, 223–9
 domestic (extant) plants 246–9
 new plants 245–6
 sui generis systems, and 236, 238–9, 242, 245–6
 technologically advanced 238
 Breyer, Justice Stephen 6–7
 broadcasting 23, 28, 29, 328, 332, 333
 organizations 23, 29, 52, 57
 ‘brown bagging’ 239
 Budapest Convention on the Deposit of Micro-organisms 56
 Budapest Initiative (2001) 15
 Bulgaria 283, 292
 Burk, D.L. 42
 Burundi 182
 Bush, President 141
 business practices, laws focusing on 274–5, 296
 Business Software Alliance 141
 CAFTA 53
 CAFTA–DR 342, 370–85, 389
see also model law for protection of undisclosed data
 CAMBIA 259
 Cambodia 24, 27, 150, 157
 Canada
 Bolar exemption 110–11
 branded drugs 151
 database protection, IPRs and 9
 generics sales 116
 GIs, and 283, 292
 passing off 274
 Patent Act 110–11
 test data protection 378

- capacity-building 21, 218, 349, 357, 403
- Caribbean countries 29, 30
- Carroll, M.W. 42
- Cartagena Protocol on Biosafety 221
- Central America Free Trade Agreement (CAFTA) 53
 - US/Dominican Republic, and (CAFTA-DR) *see* CAFTA-DR 342, 370-85, 389
- Central American Corn Improvement Programme 349
- Central American region 341
- see also* innovation and public research in Central America
- certification trademarks (CTMs) 275-6, 279-81, 284, 285, 287, 290, 296
- Ceylon tea 289-90
- Changtavorn, T. 238
- Charles S. Loeb Pipes, Inc, Re* [1975] 275
- Chaudhuri, S. 81-4
- checks and balances 61, 363, 363-9
- Chile
 - collecting societies 30, 35
 - copyright 23
 - data protection 372, 375, 378, 379, 382-3, 384
 - IP decision-making 23
 - US FTA 379, 384
- China
 - collecting societies 29, 48
 - copyright 37, 41, 44-5, 46, 48
 - counterfeiting and piracy in 37-8, 40, 45, 46, 47-8
 - database protection, IPRs and 9
 - dispute and relations with US 37, 46, 47
 - drug supply 169
 - ARV drugs 130
 - economic disparity in 40
 - emerging economy 397
 - food and medicines 257
 - functional bureaucratic system 44
 - generic companies 148, 149
 - GI obligations, implementation of 284
 - IP reforms in China 37-49
 - courts, use of 40-41, 47, 48
 - enabling environment for IP protection 45-7
 - improvements, micro-level 47-9
 - recent 37
 - regional disparities 38-41
 - sectoral disparities 41-5
 - passing off 274
 - patents 39, 43, 44, 45, 47, 48
 - pharmaceuticals 148, 151, 162
 - research 159, 258
 - trademarks 44-5, 47
 - UPOV, and 241, 242
 - WTO accession, effects of 39-40
 - China United Intellectual Property Protection Centre (CUIPPC) 45
 - Chow, K.B. 39, 40
 - CISAC 29, 30
 - civil society *see* consumers groups and civil society
 - click wrap licences 47
 - Codes of Conduct on Biotechnology 218
 - Cohen-Boyer method 11
 - collaboration
 - agreements 1-8, 353
 - research and development 256-7, 349, 355-6, 357
 - India, in 115, 122-4, 127-8, 133-4
 - collecting management and societies 27-30, 34-6, 48, 61
 - Colombia 35, 148, 377
 - Commission on Intellectual Property Rights (CIPR) xxi, 28, 43, 47, 106, 211
 - Common Market for Eastern and Southern Africa (COMESA) 176, 197-200, 201
 - commons, protected 258-9
 - Commonwealth of Independent States (CIS) 120
 - Community Forests Bill (Draft 1992, amended 2006), Thailand 244
 - Community Intellectual Rights Protection Act (Draft 2001), Philippines 244, 261
 - community rights
 - Asia, and 263, 266
 - community, definition of 228
 - generic use restriction technologies, and 223-5, 227-31
 - sui generis* systems, and 241, 263-4
 - compact discs (CDs) 30
 - competition
 - authorities 364, 366, 367, 369
 - independent, competition law and 188
 - sub-Saharan African countries 188, 189, 196, 197, 199-201
 - IPRs suppressing 5, 7
 - laws 61, 134, 144, 198, 199, 201, 363-9
 - access to medicine, and 187-97
 - developing countries, and 366-7
 - policy 61, 176, 307
 - access to medicines, and 187-97
 - development 197-201, 367-9
 - enforcement 196, 197, 199-200, 366, 367
 - monopoly abuse addressing 61
 - multi-lateral agreement 367
 - publishing industry 307
 - regional development 197-200

- sub-Saharan Africa, affordable medicines and 176, 187–8, 192, 193–4, 196, 201
 - regional policy 199–200
 - rules 402, 403
- competitive funds 358
- competitiveness 60, 143, 159, 168, 217, 309
 - Central American region 341–4, 354, 358
 - EPAs, and 394
- compliance 280
 - Arab countries, IP, and 51, 59
 - compulsory licence, FTA provisions and 166
 - developing countries by 45, 185
 - geographical indications 273, 294
 - IGO, specifications defining 277
 - patent 120
 - plant variety protection 245
 - TRIPS, and 185, 245, 273
 - compliant with 98–106, 112, 134–5, 181–2, 185, 225, 289, 324
 - WTO questionnaire 288
- compulsory licences and licensing 12, 71, 78, 87, 170
 - Brazil, and 180
 - competition, and 365
 - compliance, FTA provisions, and 166
 - developing countries, and 105–6
 - Doha Declaration 99–100, 106, 108
 - generic industry in India, and 105–9, 132–3
 - GURTs, and 227, 228
 - Kenya 182, 183–4
 - public
 - health, and *see under* public health
 - protection
 - interest *see under* public interest
 - South Africa, and 180–81, 195
 - Thailand, and 144–5, 160–61, 164, 165–6
 - WTO General Council 30 August decision 179
 - Zambia 185–6, 187
- computer
 - hardware, affordability of 304
 - programs 13, 24, 144, 328, 334
 - software 13, 23, 48, 60, 311
 - open source *see* free and open source
 - software (FOSS)
- see also* data; databases
- confidentiality 345–7, 385, 400
- Connett-Porceddu, M. 353
- Conrad, A. 275, 277, 281
- consultation and participation 21, 22, 25, 27
- Consultative Group on International Agricultural Research (CGIAR) 240, 258
- consumers and civil society
 - Arab countries, in 55, 61
 - development-orientated IP policies 63–4
 - checks and balances 61
 - developed countries, in 63–4
 - generics sales 116
 - impact of changes in IP system 48–9
 - perception 294–5
 - protection of 274, 285
 - US-Thailand FTA, and 142
- Consumer Protection Act of India 285
- Convention on Biological Diversity (CBD) xx, 26, 217–18, 221–3, 350
 - sui generis systems 224–5, 235, 237, 239–40, 245, 250–53, 255
 - traditional knowledge, and 264
 - Working Group 227, 264
- see also* Bonn Guidelines
- copyright
 - access to knowledge 303–4
 - see also* education and access to knowledge *under* southern Africa
 - administration, collecting societies and 27–30
 - Arab countries, in *see under* Arab countries
 - China, in *see under* China
 - databases 8, 9
 - EU Directive 13
 - exceptions 314
 - international trade rules 319–21
 - photocopying, and *see* photocopying
 - piracy and counterfeiting *see* piracy and counterfeiting
 - protection 7, 16, 55, 311, 319, 331, 333–4, 336
 - periods xx
 - TRIPS Plus 55
 - public benefits 6–7, 12–14
 - regimes 27, 304, 323–5
 - southern Africa, law in 319–37
 - exceptions 325–34
 - regimes 323–5
- Copyright Act (1910), UK 322
- Copyright Treaty, WIPO (1996) 13
- Cornes, R. 278
- Correa, C.N. 157, 158, 345
- Costa Rica 24–5, 27, 148, 370
- Cotonou Agreement 398, 399
- Council for Scientific and Industrial Research (CSIR) 102–3, 124, 126, 133
- counterfeiting and piracy *see* piracy and counterfeiting
- courts, specialized 22, 40–41, 265
- Creative Commons (CC) 61
- creators' rights 314
- cross-licensing 352
- Cuba 29

- Cultural Revolution 44
- customary
- dispute settlement 265
 - knowledge and protocols 170, 264
 - laws and practices 228–9, 244, 248, 263–4, 265, 322
 - names 291–2
 - protocols 240, 257, 262, 263–4, 265, 266
 - rights 237
 - societies 224
- Darjeeling tea 274, 279, 284–8, 292, 296
- data
- copyright protection extended 311
 - databases *see* databases
 - exclusivity *see* data exclusivity
 - undisclosed and test data *see* model law for protection of undisclosed data
- data exclusivity 10–11, 15
- Arab countries, and 55, 57, 59
 - rules 5, 10
 - US-Thailand FTA, and 145, 164
- Database Directive 8–9
- databases
- copyright protection extended 311
 - non-original, IPRs, and 7, 8–9, 15, 60
 - traditional knowledge, and 261–3, 264
- Deaton, A. 81–2
- declaration of origin 228, 229, 230
- Decree 2085 377
- Decree 30–2005 of Guatemala *see under* Guatemala
- Department for International Development 106
- developed countries 63, 342
- access to knowledge 313, 319, 325
 - bilateral agreements 140, 241
 - checks and balances 61, 363, 364, 365
 - collecting societies 29
 - competition law, IP and 190
 - consumers groups and civil society, IP and 63–4
 - drug patents 120
 - enforcement, and 390
 - exploitation 213
 - FTAs with Arab countries 64–5
 - harmonization approach 37
 - ICT, and 304
 - innovations, protection of 237
 - IP protection 60, 363
 - life form patents 60, 211–12, 237
 - multilateral forums 140
 - patent offices 121, 167
 - patentability, scope of 101
 - R&D *see under* R&D
- see also* developing countries; least developed countries
- developing countries 21–32, 51–3
- access to knowledge *see* education and access to knowledge *under* southern Africa
 - digital content, restricted use of 312
 - checks and balances, IPRs and 61, 142, 363–9
 - competition laws, and 366–9
 - compulsory licences *see under* compulsory licences and licensing
 - consumers groups and civil society 64
 - education *see* education and access to knowledge *under* southern Africa
 - enforcement, and 390, 401
 - foreign direct investment 140
 - Friends of Development (FOD) group 63
 - FTAs 52
 - generic industries 71, 168
 - see also* India; Thailand
 - GURTs, and *see* genetic use restriction technologies (GURTs)
 - IGOs and GIs, and *see* indications of geographical origins (IGOs) and GIs
 - international trade negotiations 166–7
 - IPRs and 61, 142, 363–9
 - least developed *see* least developed countries
 - less developed 15
 - medicines, access to 169–70
 - competition law and policy, and 187–97
 - natural resources for 170
 - prices 365–6
 - national variations in IP decision-making 23–30
 - administrative organization of IP offices 23–4
 - challenges and development implications 30–32
 - coordination of enforcement efforts 26–7
 - copyright administration and collecting societies 27–30
 - intellectual property offices (IPOs) 23–4
 - interministerial coordination 24–5
 - public consultations 27
- patents 89–90, 210–12
- access to medicines 134–5
 - life forms 60, 237
 - monopoly-inducing, effects of 72–89
 - pharmaceutical 71, 134–5, 140
- pharmaceuticals production 147–8
- public policy framework 23
- reform 21–32
- scope of national IP decision-making 21–2
- sectoral disparities 41, 43

- soft law, and 52
- sui generis systems, and 237
- technical assistance, needs and 62, 368
- technology transfer 161, 167–8, 218, 368
- TRIPS, and 43, 53–4
- TRIPS-Plus, and 54–5, 71, 142
- UPOV, and 57
- WIPO 216–17
- WTO General Council 30 August decision 179
- see also* Arab countries; sub-Saharan African countries
- Development Agenda WIPO xxii–xxiii, 52, 53, 60, 61, 403
 - Arab countries participation 63
 - technical assistance, and 62
- Dhar, B. 241
- Diamond v Chakrabarty* [1980] 212
- digital
 - content, restricted use of 312, 335–6
 - environment 140
 - media 46
 - rights management (DRM)
 - anticircumvention provisions, and 12–14, 16
 - technology 7
 - works 56, 336
- Digital Millennium Copyright Act (1998) (DMCA) 13, 312
- digitization 325, 335–6
- Diplomatic Convention, WIPO (1996) xxiii, 9, 14
- Directives
 - database protection (96/9/EC) 8–9
 - harmonizing copyright (2001/29/EC) 13
 - intellectual property enforcement (IPRED 1 and 2) 391, 394–7, 398–401
 - undisclosed data, protection of (2001/83/EC, amended 2004/27/EC) 377
- disclosure of origin requirement 240
- discrimination *see* non-discrimination
- dispute settlement
 - Canada and European Union 110–11
 - customary 265
 - sui generis systems 265
 - US and China 37, 46
 - WTO xix, 167, 216, 224, 273, 292, 390
- distinctive signs 276, 295
- DNA fingerprinting 253
- doctors 366
- Doha Declaration on the TRIPS Agreement and Public Health (2001) xxii, 52, 53, 142
 - compulsory licences *see under* compulsory licences and licensing
 - developing countries, and 164
 - drug patents 71
 - GIs, and 282–3
 - Ministerial Declaration 99
 - model law for protection of undisclosed data, and 371, 384
 - Patent Act, India, and 99
 - sub-Saharan countries, and *see under* sub-Saharan African countries
 - sui generis systems 237
 - trade negotiations 140
- see also* public health protection
- domestic plant variety protection *see under* sui generis systems for plant variety protection
- domestic regimes 277–8
- dominant position, abuse of 188–9, 198, 307, 364
- Dominican Republic 342, 351
 - see also* CAFTA-DR
- Dougherty, S.M. 44, 45–6
- Dr Reddy's Laboratories 114, 117–19, 121, 123, 125, 127, 133
- Drahos, P. 292, 303
- drama rights 28, 30
- Drug Development Promotion Foundation (DDPF) 126–7
- drug master files (DMF) 117–18
- Drug Price Competition and Patent Restoration Act (1984) *see* Hatch-Waxman Act (1984)
- drugs *see* generic; medicines and drugs
- Drugs Price Control Order (DPCO) 124–5
- duration of a patent 188
- 'DUS' requirements 238, 242, 248, 251
- Dutfield, G. 54, 238, 239
- Dyer Meakin Breweries v The Scotch Whisky Association* [1980] 279
- East African Community (EAC) 182, 201, 231
- Eastern Europe 40, 151
- eastern and southern Africa (EAS)
 - genetic resources *see under* genetic resources
 - GURTs *see under* genetic use restriction technologies (GURTs)
 - southern Africa *see* southern Africa
 - sub-Saharan Africa *see under* sub-Saharan African countries
- Eby Konan, D. 76
- Economic and Social Commission for Asia and the Pacific 162
- Economic Commission for Latin America and the Caribbean (ECLAC) 370
- Economic Community of West African States (ECOWAS) 391, 397–403
- economic control, localizing 273, 287, 293–4

- economic literature, review of 71–90
 - current econometric analysis 80–84
 - parallel imports, impact of 84–7
- first generation partial equilibrium models 72–7
- second generation partial equilibrium models 77–80
- economic partnerships agreements *see* EPA enforcement provisions
- Economides, N.S. 275
- Economist 151
- ECOWAS 391, 397–403
- Ecuador 35
- education and access to knowledge 61, 63
 - southern Africa *see under* southern Africa *see also* knowledge
- EEC Treaty 294, 296
- Egypt 56, 57, 63, 147
 - IP decision-making 23, 26, 27
- Eli Lilly 115, 119, 122–3, 141
- emergencies *see under* public health protection
- enabling environment for IP protection 45–7
- Enaleni Cipla 178
- encryption technology 46
- enforcement
 - Arab countries 51, 55, 57, 59
 - Asia and GI origins, and 280, 288
 - Central America 342, 345, 347–8, 350
 - China 38–9, 41, 44–7, 49
 - competition laws 367–9
 - coordination efforts 21–3, 26–7
 - developing countries 26–7, 366
 - development of 367–9
 - EPAs, of *see* EPA enforcement provisions
 - GURTS, and 224–5, 229–30
 - India 99
 - southern Africa 196–7, 199, 311, 313–14, 318–20, 337
 - sui generis systems, and 237, 244–5, 265
 - TRIPS, and 390–94, 397–8, 401–2
 - undisclosed data, and 374
 - UPOV Convention 216–17
 - WIPO 216
 - WTO 216
- enhanced market access 363
- environment 53, 58, 61–2, 141, 143, 184, 235
 - genetic use restriction technologies, and 211, 217–21, 223, 226–8
- EPA enforcement provisions 390–403
 - ECOWAS countries, and 397–403
 - Cotonou Agreement 398, 399
 - damages basis 400–401
 - evidence gathering 400
 - free trade zones 401
 - intermediary liability 400
 - loss of flexibility 398–9
 - positive agenda 401–3
 - third party rights 399–400
- EU intellectual property enforcement framework 391, 394–7, 399–403
- TRIPS enforcement framework 391–4
- Ernst and Young 39
- essential
 - facilities 364
 - medicines *see* medicines and drugs
- essentially derived varieties (EDVs) 238
- Ethiopia 182, 223, 229–30
- Euro-Mediterranean association agreements (AAs) 56–7
- Euro-Mediterranean Free Trade Area (EMFTA) 56
- Europe 119, 242
- European Agency for the Evaluation of Medicinal Products 376, 385
- European Commission 394, 396, 398, 399
- European Court of Justice 8–9
- European Free Trade Association (EFTA) xix, 56, 57
- European Neighbourhood Policy (ENP) 57
- European Parliament 396
- European Patent Convention 57
- European Patent Office (ENO) 121
- European Union (EU)
 - bilateral agreements 56–7, 292–3
 - Bolar exemption 110–11
 - Canadian wines and spirits 292
 - competition law 364
 - Directives *see* Directives
 - enforcement, and 390, 391, 394–7, 399–403
 - ENP Action Plans 57
 - Euro-Mediterranean association agreements (AAs) 56–7
 - exports to 291
 - FTAs xix, 52, 56, 124
 - GIs, and 283
 - harmonization approach 37
 - IP standard setting 56
 - licences 364
 - pharmaceuticals 71
 - technical assistance 368–9
 - WTO decision (30 August 2003) 382
- evergreening 144
- exception, national emergency as 132
- excessive prices *see under* medicines and drugs
- exclusion from patentability 58, 221
- exclusionary acts 189–90, 192, 195
- exclusive marketing rights (EMRs) 98–9
- exclusive rights 71, 75, 164, 165, 275
 - checks and balances, and 363–9
 - South Africa, and *see under* South Africa

- test data, and *see* model law for protection of undisclosed data
- exhaustion of rights 71, 182
- expenditure on R&D 126, 113–20, 133, 159, 169, 222, 358, 365
- experimental use exception 110
- export prohibition 162, 165
- extension of patent term 58, 143, 145, 164
- fair
- dealing 311, 313, 315, 322, 325–34, 337
 - practice 320–21, 325–34, 337
- Fair Trade movement 259
- Falcon, W.P. 248
- FAO International Treaty *see under* Food and Agriculture Organization (FAO)
- farmers
- exemption 223, 225, 239
 - GURTs, and 213, 221
 - networks 235, 236
 - organizations 142, 260
 - privilege 225, 228, 239
 - research, and 227
 - rights 221, 222, 235, 239, 241
 - definition of 226
 - sui generis systems 245
 - Asia, and 236, 243–4, 259–60, 261
 - domestic (extant) plants 246–9
 - GURTs, and 224, 226–9, 230–31
 - local plant varieties 250
 - seeds 213–14, 218, 222, 225, 227–9, 239, 259–60
 - exchange networks 252, 258
 - smallholders 221, 222
 - technologically advanced 238
 - traditional knowledge 261
 - variety-use restriction, and *see* genetic use restriction technologies (GURTs)
- see also* plants; seeds and seed industry
- Federal Drug Administration *see* Food and Drug Administration, US (FDA)
- Federal Food, Drugs and Cosmetics Act (1938) 377
- Federal Register 38–9
- Feist Publications v Rural Tel. Serv. Co* [1991] 6, 8
- film industry 30
- Fink, Carsten 47, 58, 78–80, 81, 84
- first-line ARV drugs 131–2
- fixed-dose combinations (FDCs) 129, 185
- flexibilities *see under* TRIPS
- Flitner, M. 244, 248
- folklore 23, 55, 217–18, 219, 237, 326
- food 257
 - safety and standards 274
 - security and resources 141, 209, 214, 218–20, 226–9, 235, 260–61
 - sovereignty 215, 254–5, 260–61
- Food and Agricultural Organization (FAO) xxi, 216, 218, 220–21, 226, 231, 235, 240
- International Treaty *see* International Treaty on Plant Genetic Resources (ITPGRFA)
- Food and Drug Administration, US (FDA) 101, 102, 116–18, 119, 121–2, 151, 377
- sub-Saharan countries, and 175, 177–8, 181
- foreign direct investment (FDI) *see under* investment
- Fowler, C. 248
- France 30, 116, 147, 148, 151
- franchise contracts 24
- Frank, R.B. 88
- free and open source software (FOSS) 304, 310, 354–5
- free trade agreements (FTAs) xix, 52, 58, 141, 142, 363, 390
 - Arab countries, and *see under* Arab countries
 - EFTA, and *see under* EFTA
 - EU, and *see under* EU
- IPRs
 - compulsory licences, and 12
 - data exclusivity 10–11
 - expanded description of exclusive rights in xx
 - nature of legal protection 5
 - protection periods xx
 - least developed countries, and 54
 - TRIPS-Plus, and 54–5
 - US, and *see under* United States
- Free Trade Area of the Americas (FTAA) 9, 54
- free trade zones 401
- Friends of Development (FOD) group 63
- Frischtak, C.R. 42
- FTA Watch 142
- functional bureaucratic system, China in 44
- funds 357–8
- Fungizone matter 193–4, 196
- G8 xx, 390
- General Administration for Quality Supervision Inspection/Quarantine (AQSIQ) xiii, 284
- General Agreement on Tariffs and Trade (GATT) 217
- see also* Uruguay Round of Trade Negotiations
- General Council 30 August Decision, WTO *see under* sub-Saharan African countries
- generic drugs 151–4
 - advertising *see under* medicines and drugs

- ARV *see under* HIV/AIDS
 brand loyalty 88, 152, 153, 166
 branded 151–3, 164
 companies and producers 71, 87–9, 103–5, 148, 149
 South Africa, in *see under* South Africa
 competition and competitors 71, 125, 149, 164, 168, 193
 development of innovative drugs 120–22, 133
 entry 117–22, 145, 164, 195, 370
 industry *see under* India; Thailand
 novel drug delivery systems (NDDS) 119–20, 122, 127–8, 133
 prices *see* prices and pricing *under* medicines and drugs
 voluntary licences *see under* Kenya; South Africa
 generics 116–22, 291–2
 genetic resources 345, 350,
 eastern and southern Africa, and 211, 217–18, 220–21, 223–6, 229–30
 Intergovernmental Committee on 217
 International Treaty on Plant Genetic Resources for Food and Agriculture 240–41
 misappropriation measures 60
 sui generis systems for plant variety protection 235–7, 239, 242, 248
see also plants
 genetic use restriction technologies (GURTs)
 xv, 46, 243, 260
 eastern/southern Africa, sustainable development and 209–31
 assessment of impact 226–7
 benefit sharing 229–30
 breeders' rights 223–9
 CBD, and 217–18, 221–5, 227
 community rights 223–5, 228–31
 definition of GURTs 214
 developing countries, and 210–13, 219–20
 development agenda 219
 ESA approach to IP protection 222–4
 farmers' rights 221–4, 226–31
 GURTs, nature of 214–16, 220–21
 implementation and regulation 227, 230–31
 international trends 216–18
 IP protection, impact in ESA of 221–2, 226–7
 IPRs, and 220–21, 229
 seeds, development and 209–13
 sui generis regimes, and 224–7, 228–31
 system costs, IP 218–19
 TRIPS, and 220–21, 227
 WIPO 216–18, 231
 WTO Development Agenda 219
 genetically modified crops and organisms 214, 221, 235, 238, 260
 Geneva Convention 37
 geographical indications *see* indications of geographical origins (IGOs) and GIs
 Geographical Indications Act (2000), Malaysia 289
 Geographical Indications Act (2004), Thailand 290
 Geographical Indications of Goods (Registration and Protection) Act (1999), India 279, 285
 Geographical Indications of Goods (Registration and Protection) Bill, Pakistan 289
 Georgia 57
 Germany 49, 116, 147, 148, 150, 151
 Gervais, D.J. 273
 Ghana 26, 27, 162, 318
 GlaxoSmithKline
 generic industry in India, and 103, 108, 113, 115, 119, 123, 130
 Kenya, and 182, 183
 South Africa, and 176–9, 190–93, 194
 global
 information system 241
 knowledge economy 342
 pharmaceutical market and producers 115, 175
 Global Fund to Fight AIDS Tuberculosis and Malaria 118, 129, 175
 Goeschl, T. 46
 Goldberg, P.K. 81–4
 Goodman, D.S.G. 38
 government
 incentives for R&D, Indian 126
 licences *see* licences
 procurement 141
 subsidies 357–8
 use provisions
 competition, and 365
 enforcement, and 390–91
 Kenya *see under* Kenya
 Zambia *see under* Zambia
 Government Pharmaceutical Organization (GPO) xv, 149–50, 152, 154–6
 Grabowski, H.G. 87–8
 Graham, J.L. 41
 Grameen Bank 261
 grant-back 162
 Grazioli, A. 279, 281, 282
 Guatemala 379, 384
 Guinea-Bissau 23

- Gulf War 157
 Gupta, A.K. 251, 261
- Halsbury, Lord 274
 Hamre, J.J. 38
 handicraft industries 281, 289, 290
 Harare Protocol on Patents and Industrial Designs (1982) 212
 Hart, Keith 318
 Harte-Bavendamm, H. 275
 Hatch-Waxman Act (1984) 72, 87, 116, 118, 122
 Hayden, E.W. 264
Hazel Tau and Others v. GlaxoSmithKline and Boehringer Ingelheim 190–93, 194, 196
 Heald, Professor 43, 45
 health *see* public health protection
 HIV/AIDS 142, 175–6, 179, 185, 191, 193, 384
 drugs 98, 103, 177, 179, 188, 191–2, 193, 211
 antiretroviral (ARV) drugs and therapy
 access to
 excessive pricing, and 190–94
 free ARV treatment 128
 Indian pharmaceutical industry and 128–33, 134
 Brazil 130
 China 130
 generic 117–18, 128
 price 118, 128, 129, 131–2, 134
 product patents and future of ARV 130–33
 Thailand, and 150
 treatment, free 128, 129
 sub-Saharan African countries, and *see* *under* sub-Saharan African countries
see also medicines and drugs
 holographic labels 46
 Honeybee Network 263
 Hong Kong 49, 241–2, 274
 Horner, Mark 311
 Horsley, J.P. 47
 Human Development Index 185
 Hungary 292
- incrementally modified drugs (IMDs) 100, 101–2, 121–2
- India
 competition laws 366
 Darjeeling tea 284–8
 drug supply 128–33, 169
 emerging economy 397
 food and medicines 257
 FTA 124
 generic pharmaceutical industry 97–135, 147, 148, 149, 162
 Patents Act *see* Indian Patents Act (1970)
 recent performance 112–24
 alliance-building efforts 122–4, 133
 history 112–13
 R&D organization 115–16
 R&D spending 116–22
 technology and R&D 113–15
 GIs, and 283, 284–8
 government, role of 124–8, 133
 IP decision-making 23
 collecting societies 30
 coordination of enforcement efforts 26–7
 interministerial coordination 25
 public consultations 27
 ITPGRFA, and 240
 opposition proceedings, India 101, 109
 passing off 279
 piracy 316–17
 prices of pharmaceuticals 154
 see also prices and pricing *under* medicines and drugs
 PVP laws 242, 244–9, 255, 259–61, 265
 research and development 113–24, 258
 alliance-building efforts 122–4, 133
 government promotion of 124–8, 133
 public-private partnership 126–8
 innovative drug development 120–22, 133
 novel drug delivery systems (NDDS) 119–20, 122, 127–8, 133
 organization 115–16
 pharmaceutical industry, in 146–7
 spending on generics 113–20, 133
 seed exchange networks 252
 sui generis systems *see* Asia *under sui generis* systems for plant variety protection
 traditional knowledge 261–3
- Indian
 Biodiversity Information System (IBIS) 263
 Biological Diversity Conservation Act 252–3, 255, 263, 265
 Bill (2002) 244
 Council of Medical Research (ICMR) 126
 Patents Act (1970) 124, 125, 129, 131, 132, 133, 134
 amendments under TRIPS 98–101
 analysis of amendments 101–12
 Bolar exemption 109–11
 future of generic producers 103–5
 history 97
 opposition proceedings 109
 parallel imports 111–12
 patentability, scope of 101–3
 Protection of Plant Varieties and Farmers' Rights Act (PVPFR) 243

- indications of geographical origins (IGOs) and GIs 273–96
 - bilateral agreements 292–3
 - developing countries 273
 - domestic considerations 281–2
 - designing domestic regimes 277–8
 - economic control, localizing 293–4
 - generics 291–2
 - implementation, Asia in 284–91
 - China 284
 - India 284–8
 - Indonesia 288
 - Malaysia 288–9
 - Pakistan 289
 - Sri Lanka 289–90
 - Thailand 290
 - Vietnam 290–91
 - international legal obligations 278–81
 - laws focusing on business practices 274–5
 - levels of protection, 273, 282–4, 290, 291
 - segment markets 294–5
 - special means of protection 276–7
 - trademark law 275–6
 - TRIPS, and 52, 60, 273, 274–84, 285
 - WTO study 276–7, 279, 296
- indigenous
 - communities 218, 221–2, 224, 227–8, 239–40, 244, 248, 254–5, 261, 263–4
 - see also* community rights
 - copyright 323–4
 - knowledge 213, 278
 - languages 308
 - laws *see under* customary
 - material and resources 23, 170, 254
 - medicines 170
 - pharmaceutical industries 97, 148
 - plants 286, 290
 - R&D 124–6, 158
 - rights 241
- Indigenous Peoples Rights Act (1977), Philippines 244
- Indo-China 157
- Indonesia 26–7, 30, 141, 242, 250, 288
- induced innovation 76, 89–90
- industrial designs 24, 212
- industrial property 212
 - sub-Saharan Africa countries 181–4, 200
 - Thailand 145, 157, 160
 - undisclosed data, and 375, 378, 383
- Industrial Property Act Kenya (2001) 181–2
- Industrial Property Law No. 19.996 (1996), Chile 378, 383
- information technologies 304, 312, 342–3
- innovation xxi
 - Bayh-Dole Law (1980) 344
 - Central America *see* innovation and public research in Central America
 - development of innovative drugs 120–22, 133
 - funds, agriculture 357
 - IPR impact on 5–8
 - national innovation systems 341, 358
 - non-exclusive use of 355
 - promoting 6, 59, 60–61, 394
 - regulations, organization and internal 349
 - trade agreements, developing countries and 140
- innovation and public research in Central America 341–59
 - agro-biodiversity and plant breeding 343–4, 349–50
 - Bayh-Dole Law (1980) 344
 - CAFTA-DR 342
 - confidentiality, preservation of 345–7
 - environment, IPRs for 342–3
 - IP acquisition, maintenance and enforcement 347–8
 - IPR management 343–5
 - non-IPR mechanisms encouraging 353–5
 - promotion of 355–8
 - regulations, organization and internal 349
 - third-party ownership of IPRs, impact of 350–53
- Instituto Nacional da Propriedade Intelectual, Brazil (INPI) 24, 25
- intellectual property (IP)
 - acquisition, maintenance and enforcement 347–8
 - Arab countries, and *see* Arab countries
 - decision-making *see* developing countries
 - developments and trends 51–5
 - institutional level, at 51–3
 - increasing complexity of international standard-setting 52–3
 - proliferation of forums and processes in IP standard-setting 51–2
 - substantial level, at 53–5
 - need to integrate development dimension in IP 53–4
 - TRIPS Plus trend 54–5
- disputes *see* dispute settlement
- EFTA FTAs 57
- enforcement *see* enforcement
- Euro-Mediterranean association agreements, and 56–7
- international trade rules 319–21
- legislation 21, 61, 209, 220
- management committees 349
- offices (IPOs) 23–4
- see also* offices *under* patents

- policies, integrated 61–2
 - protection, GURTs and *see* genetic use restriction technologies (GURTs) outside IP regime 46–7
 - reforms *see* Arab countries; China
 - rights acquisition 345, 347–8
 - standard setting 56, 62–3
 - system costs 218–19
- Intellectual Property Act (2003), Sri Lanka 289
- intellectual property rights (IPRs)
 - checks and balances, and 61, 142, 363–9
 - commodification of information 5–6, 8, 15
 - competition suppressing 5, 7
 - data exclusivity *see* data exclusivity
 - databases protection *see under* databases
 - developing countries 61
 - digital rights management *see* digital rights management
 - domestic enforcement xix–xx
 - Euro-Mediterranean association agreements, and 56
 - GURTs, and *see under* genetic use restriction technologies (GURTs)
 - information access and data control 5–9
 - innovation, impact on 5–8
 - licences, compulsory 12
 - management 343–50, 351, 353, 355, 358
 - patents on basic research tools *see under* research
 - protection, nature of 5, 216
 - public benefit and interest 5–14, 61
 - purposes 6–7
 - rights in basic information 5–16
 - new proposals 14–16
 - sustainable development, and 210–13
 - third party ownership, under 350–53
 - trade and investment frameworks, and 57–8
 - TRIPS, and 363–9
- Intergovernmental Committee on Intellectual Property, WIPO (IGC) 217–18
- intermediary liability 400
- International Agricultural Research Centres (IARCs) 240, 257
- International Centre for Trade and Sustainable Development (ICTSD) xxi, 237, 370, 245
- International Centre of Economic Policy for Sustainable Development (CINPE) 370
- International Confederation of Societies of Authors and Composers (CISAC) 29, 30
- International Convention for the Protection of New Varieties of Plants *see* UPOV
- International Court of Justice 216
- International Federation of Phonographic Industries (IFPI) 30
- International Intellectual Property Alliance (IIPA) 37, 141
- international legal obligations 21, 236–41, 244, 278–81
- international trade rules 319–22
- International Treaty on Plant Genetic Resources (ITPGRFA) xxi, 223, 226, 235, 250, 252
 - multilateral system 240–41, 257–9
- International Union for the Protection of New Varieties of Plants *see* UPOV
 - China, and 37
- INTERPOL 390
- 'inventions ownership definition' 348
- investment
 - Arab countries, in 53, 58, 59
 - agreements with US 57–8
 - bilateral investment treaties *see* bilateral investment treaties (BITs)
 - China, in 40–42, 46
 - climate 156
 - data exclusivity 10, 15
 - database protection 8
 - foreign direct (FDI) 41, 140, 166
 - patents, and 156–8
 - IPR, as 58
 - open 358
 - pharmaceutical research, in 146, 366
 - trade-led 124
 - United States-Thailand FTA, and *see under* Thailand
- Iran 29
- Iraq 29
- Israel 57
- Italy 116, 147, 150, 151, 154, 158
- Jamaica 23, 24–5, 29
- Japan 9, 29, 30, 49, 116, 241, 291, 368
 - pharmaceuticals 147, 148, 151
- Jasmine rice 249
- Jia, P. 81–4
- Jordan 29, 56, 57, 58, 59, 379
- Kandan, Dato, V.L. 288
- Kenya 29–30, 229–30
 - COMESA 197
 - Darjeeling tea 285, 286
 - drug prices 182
 - GIs, and 283
 - government use provisions 184–5
 - Industrial Property Act (2001) 181–3
 - pharmaceuticals production 148
 - UPOV Convention 212, 223
 - voluntary licences 182, 183, 184
- WTO General Council 30 August decision implementation 181–5

- Kenya Industrial Property Institute (KIPI) 183, 184
- Knaak, R. 273
- knowledge
 access to (AK2) 60–61, 63, 303–4
 digital content 312
 southern Africa, in *see under* southern Africa
 customary 170, 264
 dissemination 61, 218, 319, 347, 367
see also technology dissemination
 economy 303, 304
 ‘On the Shoulders of Giants’ (OTSOG) 7–8
 traditional *see* traditional knowledge
see also education and access to knowledge
- Kodak 45
- Korea 48, 159, 241, 366
- Kyrgyzstan 241
- labour rights and unions 141, 142
- Laird, S. 264
- Lall, S. 158
- Lam, N.M. 41
- Lam, Thanh 291
- landraces or wild varieties 238, 247, 250–52
- Laos 148, 150, 157
- Latin America 29, 30, 51, 61, 64
- learning materials, access to *see* education and access to knowledge
- least developed countries (LDCs) 23, 54, 60, 62, 182, 321
 enforcement, and 390, 398, 401, 402
 less developed 15
- Lebanon 29, 30, 56, 57
- legal and regulatory reform *see* reform *under* developing countries
- Leibman, B.L. 47
- Lemley, M.A. 42
- Leskien, D. 244, 248
- Lesotho 200, 305, 321–2, 323–4, 326, 330–32
- less developed countries 15
- Liang, Lawrence 316–17
- Libya 57, 58
- licences 28, 46, 47, 108, 364
 compulsory *see* compulsory licences and licensing
 voluntary *see under* Kenya; South Africa
- licensing
 competition law, and 364–5
 contracts 162–3
 educational, impediments to 312–13
 technology transfer departments, and 345
 vertical licensing practices 364
- lobbying 141, 304, 314, 363
- local plant variety protection *see under* sui generis systems for plant variety protection
- localizing economic control 273, 287, 293–4
- lower-technology goods and services 42
- Lunney, G.S. 42
- Luxembourg 150
- M.S. Swaminathan Research Foundation (MSSRF) 247
- Madrid Agreement concerning International Registration of Marks 56
- mailbox 98, 101–3, 109, 132, 182
- major global pharmaceutical firms 115, 123
- malaria 185, 262, 384
 tuberculosis, and 118, 129, 153, 179
- Malaysia 141, 150, 242, 248, 288–9
- Mali 251
- Mansfield, Edwin 42, 45
- Manuel, Peter 317
- Marchenay, P. 277
- market
 access 7, 282, 343, 363, 368
 approvals 116–18, 133
 exclusivity 118, 122
 GI products, for 282–4
 segmentation 88, 313, 321, 349
- marketing approvals 145
 economic literature 85, 87, 90
 India 98, 101, 104, 110, 117, 131
 Thailand 145
 undisclosed data, and 371–2, 375–6, 381, 389
- marketing practices 149, 152–3
- marks
 certification 275–6, 279–81, 284, 285, 287, 290, 296
 collective 275–80, 284
see also trademarks
- Mashelkar, R.A. 102, 126
- Maskus, K.E. 76
 IP reforms in China 38, 39, 41, 42, 43–4, 45–6
- mass-market contracts 46
- Massey, Joseph 39
- material transfer agreements 255–8, 349, 353
 Standard Material Transfer Agreement (MTA) 240, 242, 253, 255, 257–8
- Mauritania 23
- Mauritius 23
- mechanical reproduction 28, 30
- Médecins Sans Frontières 182
- medicines and drugs 22, 52–3, 64
 access to 31, 61, 100, 111, 128, 144, 154, 164, 227, 371
 affordable pricing *see below*

- campaign 304
- competition law and policy, and 187–97
- data exclusivity, and 10, 59
- policy on 169–70
- sub-Saharan African countries, and *see*
under sub-Saharan African countries
- advertising 152–3, 155, 166, 168, 365–6
- branded drugs *see under* generic
- development of innovative drugs 120–22,
133
- food, and 257
- generic *see* generic drugs
- HIV/AIDS drugs *see under* HIV/AIDS
- incrementally modified drugs (IMDs) 100,
101–2, 121–2
- natural resources, use of 170
- novel drug delivery systems (NDDS)
119–20, 122, 127–8, 133
- patents 120, 130
 - developing countries, and 71, 134–5
 - scope *see under* patents
- prices and pricing
 - affordable 99, 108, 118, 128, 129, 131–2,
134–5
 - competition 87, 90, 116, 154, 365–6
 - controls 168–9
 - developing countries, and 365–6
 - excessive, abuse of dominant position and
188, 189–94
 - generic entry, and 87–9, 108
 - India, in 97, 129, 133
 - patents, impact of 154–6
 - Thailand, and 144, 164
- see also* price
- sub-Saharan African countries, and *see*
under sub-Saharan African countries
- United States-Thailand FTA, and *see under*
Thailand
- see also* economic literature, review of;
 - pharmaceuticals; public health protection
- Medicines and Healthcare Products Regulatory
Agency (MHRA) 119
- Merck, Sharpe and Dohme 110, 115, 123, 130,
141, 179, 180, 182
- MERCOSUR 124
- Mertha, Andrew 39, 44, 45–6
- 'me-too' drugs 133, 151–3
- Mexico 148, 292
- Micronesia 29
- Microsoft 45
- Middle East countries 29
- Middle East Free Trade Area (MEFTA) 57–8
- Middle East Free Trade Initiative 57–8
- minimum standards, TRIPS 43, 105, 141, 183,
319–20
- misappropriating 242
- misuse 5, 247, 294
 - IP rights 105–6, 165
 - monopoly powers 215
 - patents 134
 - traditional knowledge 263
- mode of production 278, 281, 294
- model law for protection of undisclosed data
370–85, 389
 - applicability 371–2
 - model provisions 372–85
- model laws 223, 223–4, 235, 323–4, 370–85
- Model Plant Variety Protection (PVP) 235,
237, 238, 241–4
- Moldova 57
- Mongolia 30
- monopolies 25, 40, 61, 127, 285, 316
 - copyright 312
 - economic literature 74, 76, 81, 84, 90
 - generics 152, 193
 - GURTs 211, 214, 215, 222, 224
 - monopolization 141, 307
 - open source biological materials 355
 - patents 72–3, 100, 131, 134, 164
 - publishing 312
 - United States 142
- Monopolies and Restrictive Trade Practices
Act, India 285
- monopolization 141, 307
- Moran, W. 276, 277
- Morocco 53, 56, 57, 58, 59, 313, 382
- most-favoured-nation treatment 237, 244–5
- Mozambique 185
- Muellbauer, J. 81–2
- Muller, R. 279
- multilateral negotiations, WTO 140, 141,
166–7
- Music Copyright Society of China 48
- music sector 28, 29, 30, 316–17
- Musunga, S. 54
- Myanmar 150, 157
- Namibia 34, 305, 201–2, 223
 - copyright regime 322, 323, 324, 326, 332–3,
335, 337
- nanotechnology 342–3
- National Biodiversity Authority, India 263
- National Biodiversity Institute (INBio) 355
- National Industrial Property Institute (INPI)
24, 25
- national innovation systems 341, 358
- national treatment, principles of 237, 244–5
- neem tree 262
- neglected diseases 128, 134
- Nepal 150, 285, 286

- Netherlands, The 147
 new chemical entity (NCE) 98, 101, 102–3, 114, 371, 377–9
 new plant variety protection *see under* sui generis systems for plant variety protection
 new uses or methods, patents for 143, 144, 185
 New Zealand 253, 283
 Nigeria 29–30, 162, 182, 315
 non-discrimination xxiii, xix, 43, 220–21, 226
 non-exclusive use of innovations 355
 non-original databases *see under* databases
 non-proprietary software 61
 non-voluntary licensing of IP rights *see* compulsory licences and licensing
 North African countries 29
 North American Free Trade Agreement (NAFTA) 141
 novel drug delivery systems (NDDS) 119–20, 122, 127–8, 133
 novelty loss 347
- Oddi, A.S. 158
 OECD 108, 111, 275, 276, 390, 397
 Okiy, B.R. 315
 Oman 58, 379
 ‘One Tambon One Product’ (OTOP) initiative 258, 290
 open access 14, 261, 310–12, 316, 337, 355, 358
 source software *see* free and open source software (FOSS)
 Ordinance on Plant Varieties (2004), Vietnam 242
 Organisation for Economic Co-operation and Development (OECD) *see* OECD
 Organization of African Unity (OAU) Model law 223–4, 235
 other products 240, 280, 282–3, 285, 289
 outstanding implementation issues 283
 ‘overnight’ patent 72, 75, 77, 82, 84
 ‘over the counter’ (OTC) market 117, 151, 152, 153
 Oxfam 259
- Pakistan 23–4, 242, 289
 Pakistan Draft Law on Access and Community Rights (2004) 244
 Palestinian Authority 56, 57
 Panitchpadki, Director-General 283
 paracopyright *see* anticircumvention
 Paraguay 36
 parallel imports (PI) and trade 71, 84–7, 111–12, 313
- Paris Convention 37, 100, 105, 144, 166, 248, 348, 375
 Parma Ham case [2001] 277
 passing off 274–5
 Patent Co-operation Treaty 37, 56, 121, 348
 patents
 applications and grants 160
 Arab countries, in *see under* Arab countries
 basic tools and findings, on 7, 11–12, 15–16
 biotechnology 211–12
 China, in *see under* China
 drugs 71, 72, 120, 124, 165
 see also medicines and drugs
 duration 186
 examination 22, 127, 263
 extension of patent term 58, 143, 145, 164
 foreign direct investment, and 156–8
 FTAs, and 13
 India, and *see* India
 infringement suits 105, 119
 inventions and utility models 24
 law and harmonization 52, 188
 litigation 103
 new uses or methods 143, 144, 185
 offices 100, 102, 109, 121, 131, 144
 role 167–8
 ‘overnight’ 72, 75, 77, 82, 84
 patentability and criteria 353
 exclusion from 58, 221, 224, 236–7
 plants and animals 59, 211–12
 scope of 71, 101–3, 165, 223
 software 60
 US-Thailand FTA, in 144
 pharmaceuticals, and *see under* pharmaceuticals
 pools 215
 revocation 143, 144, 165
 rights, abuse of 105–6, 165
 technology, impact on *see under* technology
 thickets 107–8
 TRIPS Agreement *see* TRIPS
 discriminatory protection *see* non-discrimination
 pay-per-use information commerce 7, 9, 13
 PCR enzyme protein 11
 People’s Biodiversity Registers (PeBRs) 263
 performance rights and royalties 28, 30
 Performances and Phonograms Treaty, WIPO (1996) 13
 performing rights in dramatic works 28
 Peru 27, 36, 254, 384
 Pfizer 48, 119, 123, 141, 154
 Pharmaceutical Research and Development Committee (PRDC) 126–7, 133

- pharmaceuticals
 advertising regulations, and 365–6
 agrochemical test data *see under* agricultural
 chemical products
 checks and balances, and 365–6
 competition law, and 363–9
 data exclusivity, and 7, 10–11, 15
 generic producers *see under* generic
 innovations *see* innovation
 industry and manufacturing
 structure and characteristics 146–53
 see also India; Thailand
 international trade in 148–9
 patents
 drugs, and *see* drugs *under* medicines and
 drugs
 prices, impact on 154–6
 prices 154–6, 365–6
 production 146–8
 registration, test data and *see* model law for
 protection of undisclosed data
 regulation 53
 sector 191, 401
 checks and balances 363, 365–6
 India 97, 107, 130
 Thailand 146, 151, 163, 169
 substance 103
 TRIPS, and 71, 370
see also economic literature, review of;
 medicines and drugs
- Philippines, 141
 indigenous peoples 263–4
 IP decision-making 23
 coordination of enforcement efforts 27
 public consultations 27
 PVP laws 244
 seed exchange networks 252
 sui generis systems *see* Asia *under* sui generis
 systems for plant variety protection
 UPOV-style laws 242
 utility model protection 44
- Philippines Indigenous Peoples Rights Act
 (1997) 244
- Phillips, T. 45
- phonograms 13, 28, 29, 57
- photocopying 28
 informal economy and access to learning
 materials 315–19
- Phu Quoc 291
- piracy and counterfeiting 304, 337
 Arab countries, and 57, 59
 biopiracy 213, 242, 246, 262, 263
 Brazil anti-piracy strategies 26
 China, in *see under* China
 definition 313
 educational material 318–19
 enforcement, and 402
 criminal procedures and penalties 394,
 395
 ENP Action Plans 57
 India, anti-piracy cells in 26
 informal economy context 314, 316, 318
 music sector, and 316–17
 parallel trade 313
 Peru anti-piracy strategies 27
 photocopying, and 315–19
- Plant Varieties Protection Act (2004),
 Singapore 242
- Plant Variety Protection Act (1999), Thailand
 243
- plant-derived pharmaceutical (phyto-
 pharmaceuticals) products 356
- plants
 breeders' rights *see under* breeders
 breeding 247
 Central America, in *see under* innovation
 and public research in Central
 America
 definition 225–6, 237–8
 Model Plant Variety Protection *see* Model
 Plant Variety Protection (PVP)
 protection 212, 215, 217, 219, 222–5, 229,
 344, 351, 354
 sui generis systems *see* sui generis systems
 for plant variety protection
 varieties 57, 23–5, 225, 228–9, 345, 347, 348,
 351
 protection and innovation 353–4
- plao noi shrub 262
- policy space 54, 140, 189, 202, 203
- Politics of Piracy* (Mertha) 44
- poverty, rural 260–61
- pre-grant opposition 22, 109
 prohibited 143, 144, 165–6
 post-grant reviews 22
- President's Emergency Plan for AIDS Relief
 (PEPFAR) 118, 128
 sub-Saharan African countries, and 177,
 180
- price
 competition 87, 90, 116, 154
 controls 61, 72, 75, 78–9, 81–2, 85, 89, 124,
 156, 168–9
 excessive, books in southern Africa 306–8
 medicines, of *see under* medicines and
 drugs; pharmaceuticals
- Price Control Law (1995), India 78
- Priest, E. 48
- Primo Braga, C.A. 47
- principal-agent problem 366

- Print Industries Cluster Council (PICC) 307, 312, 318–19
- printed works 28–9
- prior informed consent (PIC)
GURTs, and 228, 229, 230
material transfer agreements and 255–8
sui generis systems, and 236, 237, 239, 242, 253, 255–8, 261, 266
traditional knowledge, and 261, 264
- Priority Watch List, Section 288, 301, 397, 399
- private-public linkages 342
- process patent regime 98, 108–9, 113, 134
- product commercialization 342, 356
- products patents
India 98, 99, 101, 130–31
regime 97, 99, 100, 103, 108–9, 130–31
Thailand 154, 163
- prohibited practices 189, 195
- Proinnova Programme 346–7
- PROMECAFE Network 351–2
- Promotion and Protection of Thai Traditional Medicinal Intelligence (1999), Act 244, 248
- Protection of Plant Varieties and Farmers' Rights Act *see under* Indian
- Pterocarpus 262
- public
awareness 21
consultations 21, 22, 25, 27
domain xx, 14, 216
education and access to knowledge 303, 308, 326, 331–2
innovation and research in Central America 348, 355, 358
sui generis systems 246, 251, 253, 261
undisclosed data 375, 384–5, 389
funding 357–8
health *see* public health protection
interest and benefit 5–14, 61, 100, 165, 184, 266, 320
access and compulsory licences 228, 229, 344, 346
technical assistance, and 368–9
undisclosed data, protection of 371, 383, 384
participation 21, 22, 25, 27
performance rights 28
policy 23
objectives 49, 53, 58–62, 64, 348
space 54, 140, 187, 200, 201
private alliances and partnerships, and 22, 126–7, 355–6, 396
research centres 240, 341, 342–9, 353, 357, 358
public health protection 60
compulsory licences, and 106, 108, 382
emergencies 108, 118, 128, 132–3, 186, 191, 384, 391
GURTs, and 228, 229
HIV/AIDS *see* HIV/AIDS
IGOs, and 274
IP and, consumer groups discussing 63, 64
policies and objectives 54, 61, 140
competition law and policy, and 187–97
programmes 365
TRIPS, and 43, 51, 52–3, 55, 61, 99, 382
see also Doha Declaration; medicines and drugs
- Public Health Emergency Medicines Act (HR 3235) 108
- Public Library of Science 15
- publication 15, 104, 109, 396
education and access to knowledge 317, 321, 324, 330, 332–4
innovation and public research 345, 347
undisclosed data 376, 379, 385
- PVP laws *see* sui generis systems of plant variety protection
- radio-frequency identification (RFID) 46
- Ramsey pricing structures 365
- Ranbaxy 104, 113–14, 117–25, 127, 129–30, 133, 178
- Rangnekar, Dwijen 238, 273, 276, 279, 280, 281, 282, 285, 292
- Rao, Niranjana 285
- regional
bilateral IP negotiations, and 140–41
competition policy 176, 197–201
trade talks 141
- registers and registries 38–9, 161–3, 164, 263, 281
- regulations, organization and internal 349
- Reichenmiller, P. 58
- Reichman, J.H. 43
- Reiffen, D. 88
- related rights 29
- reform in developing countries *see* developing countries
- remedies 13–14, 198–9, 265, 390, 392–5, 400
- research and development (R&D)
breeder's exceptions 228
collaborations 256–7, 349, 355–6, 357
India, in 115, 122–4, 127–8, 133–4
developed countries 146–7, 148, 158, 159
developing countries 89–90
exceptions 71
expenditure 126, 113–20, 133, 159, 169, 222, 358, 365–6

- genetic resource innovations 239
- GURTs, effect of 227
- India, in *see under* India
- innovation, and *see* innovation and public research in Central America
- intensity 114, 120
- investment in 366
- IP protection, and 42, 235
- patents on basic tools and findings 7, 11–12, 15–16
- plant genes 251
- public sector 227
- sharing 255
- tax incentives 355–7
- Thailand, in *see under* Thailand
- traditional knowledge, and 257
- research centres 240, 341, 342–9, 353, 357, 358
- resistance to IP reform *see* China
- restrictive
 - business practices 162–3
 - clauses 162, 164, 168
 - practices 189, 320
 - vertical licensing practices 364, 366
- revocation of patents 143, 144, 165
- RiceTec patent 284–5, 289
- Roche Products Inc v Bolar Pharmaceuticals Co. Inc.* [1984] 110
- Romania 292
- Rome Convention for the Protection of Performers 57
- royalties and royalty payments 161, 166, 186, 200, 317, 318, 345, 346, 357
 - ARV drugs 131
 - collecting societies 28, 29, 30
 - compulsory licences, and 107–8
 - GURTs, and 229–30
 - patents on basic research tools 11
 - royalty stacking 108
- rule of reason 364
- rural poverty 255, 260–61
- Russia 397
- Rwanda 29, 179, 182

- Sagar, R. 253
- St Kitts and Nevis 29
- Salkever, D.S. 88
- San Paulo consensus 54
- Sandler, T. 278
- Santikarn, M. 162
- Saudi Arabia 29
- Scafidi, S. 46
- scope of patentability *see under* patents
- Second South Summit 63
- second-line ARV drugs 131–2
- sectoral disparities 41–5
- seeds and seed industry 46, 213, 214, 227, 235
- see also* farmers; genetic use restriction technologies (GURTs)
- segment markets 294–5
- Senegal 30
- services 26, 42, 118, 217, 253, 336, 397
 - Asia 253, 274–6
 - innovation and public research 343, 345–7, 354–5, 357
 - pharmaceutical industry in Thailand 141, 158, 167, 169
 - rights in basic information 8, 13
 - sub-Saharan African countries 181, 187, 189–92, 196
- Sheff, David 47
- Sherwood, R.M. 45
- shrink-wrap licences 46
- Singapore 12, 49, 159, 241, 384
- small and medium enterprises (SMEs) 341
- soft law 52
- software *see* computer software
- Somalia 29
- South Africa
 - abuse of dominant position 188, 195
 - excessive prices and 189–94, 195
 - ARV therapy 177, 177–9, 181
 - bilateral agreement with EU 292
 - books, in 306–10
 - open access 311
 - broadcasting 333
 - collecting societies 29–30
 - Competition Act (1998) 179, 188–94, 201
 - amending 194–6
 - Competition Commission 176, 179, 190–94, 364
 - competition laws 366
 - Competition Tribunal 189, 192, 195
 - compulsory licences *see under* compulsory licences and licensing
 - copyright regime 312, 318–19, 322, 323, 324, 333–4, 335, 336, 337
 - Doha Declaration 176
 - education, and *see* education and access to knowledge *under* southern Africa
 - emerging economy 397
 - exclusive rights 188–9, 191
 - generic pharmaceutical companies 177–9
 - parallel trade 313
 - Patents Act (1978) 180, 181, 183, 192, 200
 - royalty payments in 108
 - SACU and SADC 197, 200
 - UPOV Convention 212, 223
 - voluntary licences 176–7, 178, 179–80, 195

- WTO General Council 30 August decision, implementation of 176–81
- Patents Act (1978), and 180–81
- South African Customs Union (SACU) 179, 197, 198, 199–200, 201
 - access to knowledge *see* education and access to knowledge *under* southern Africa
 - copyright law *see* copyright law *under* southern Africa
 - US FTA 54, 311–13
- South America 54
- South Korea 49, 148
- Southeast Asia 40
- see also* Asia
- southern Africa
 - copyright law 31, 319–37
 - digitization 335–6
 - exceptions 321–2, 325–34
 - importation 355
 - international trade rules 319–21
 - learning materials, impact on 325–37
 - multilateral agreements, SACU and 321–2
 - regimes 323–5
 - education and access to knowledge 304–37
 - excessive pricing of books 306–8
 - government resource constraints 309–11
 - informal economy in knowledge goods 313–19
 - IP, changes to 311–13
 - open access 310–11
 - photocopying, access mechanism as 315–19
 - problems 304–13
 - unavailability and unsuitability of books 308–9
 - US-SACU FTA 54, 311–13
 - digital content, restricted use of 312
 - educational licensing and adaptation, impediments to 312–13
 - extension of copyright term 312
 - parallel trade, impediments to 313
 - enforcement, and *see under* enforcement
 - genetic resources *see under* genetic resources
 - GURTs, and *see under* genetic use restriction technologies (GURTs)
- see also* Africa; sub-Saharan African countries
- Southern African Development Community (SADC) 177, 179, 197, 199, 201
 - competition policy, and 196–7
- Spain 116
- specialized courts 22, 40–41, 265
- Sri Lanka 242, 285, 286, 287, 289–90
- Standard Material Transfer Agreement *see under* material transfer agreements
- State Intellectual Property Office 48
- state-run collecting societies 29–30
- stockpiling 110–11
- Strategy for the Enforcement of Intellectual Property Rights in Third Countries* 390, 396–7
- Subramanian, Arvind 72–5, 76, 78, 80
- sub-Saharan African countries 29
 - competition
 - authorities 188, 189, 196, 197, 199–201
 - law 176, 187–97
 - policy development, regional 197–8
 - enforcement 199–200
 - Doha Declaration, and 175, 187–8
 - eastern and southern Africa (ESA) 175–6
 - GURTs, and *see under* genetic use restriction technologies
 - HIV/AIDS, in 175
 - medicines
 - access to 175
 - competition law and policy, and 187–97, 198
 - ARV therapy 175
 - prices 175, 176
 - regional competition policy 176
 - SADC, competition policy and 196–7, 197–8
 - TRIPS flexibilities, and 175–201
 - voluntary licences
 - Kenya, and *see under* Kenya
 - South Africa, and *see under* South Africa
 - WTO General Council 30 August decision 175–6, 382
 - Kenyan implementation *see under* Kenya
 - South African implementation *see under* South Africa
 - Zambian implementation *see under* Zambia
- see also* Africa; developing countries; southern Africa
- sui generis regime
 - data, and 8–9, 15, 370
 - see also* model law for protection of undisclosed data
 - minor and incremental innovations 43–4
 - plant variety *see* sui generis systems for plant variety protection
- sui generis systems for plant variety protection 235–66
 - Asia, national initiatives in 241–4
 - PVP and TK systems 242–3
 - UPOV-style 241–2
 - components and elements of 244–66

- access and benefit sharing 252–5
 domestic (extant) plant variety protection 246–9
 enforcement and remedies 265
 farmers' rights concerns, addressing 259–60
 indigenous community rights and customary protocols 263–4
 local plant variety protection 249–50
 minimum requirements and scope of protection 244–5
 new plant variety protection 245–6
 promoting domestic and local plant innovations 258–9
 traditional knowledge protection and promotion 261–3
 wild plant variety protection 250–52
 farmers' exemption and rights *see under* farmers
 GURTs, and 224–7, 228–31
 plant breeder's exception and rights *see under* breeders
 UPOV, as 223, 225
see also UPOV Convention
 Sun, C. 48
 supply chain GI products 273, 282–4, 287–8, 290
 sustainable development *see under* genetic use restriction technologies (GURTs)
 Swanson, T. 46
 Swaziland 29, 199, 200, 305
 copyright regime 319, 322, 323, 324, 327, 334, 337
 Sweden 87, 88, 89, 147
 Switzerland 147, 148, 150, 151, 283, 292
 Syria 29, 57, 58
- Taiwan 49, 159, 242
 Tanzania 30, 182
 tax incentives 355–7
 technical advice 31, 368
 technical assistance 229, 265, 403
 assessing 62
 innovation, and 354
 IP, and 21, 31, 368–9, 399
 legislative process, and 325
 medicines, and 169
 TRIPS, and 62, 368
 WIPO 26, 52, 323, 403
- technology
 access to 162, 209
 dissemination xxi, 216, 218, 320, 347, 365, 391–2, 402
 see also knowledge dissemination
 generation 133
 genetic use restriction *see* genetic use restriction technologies (GURTs)
 innovations *see* innovation
 markets 162–3
 meaning 158
 protection mechanisms 316
 technological
 capability, patents impact on 158–63
 development and research, patents and 158–61
 protection measures 46, 56, 312, 316
 service expenses 355
 transfer xxi, 24, 59, 166, 229, 235, 365, 368, 402
 departments 345
 developing countries, and *see under* developing countries
 innovation and public research, and 345, 349, 353
 meaning 161
 new technologies 140
 patents, and 44, 164
 public policy objectives 53, 402
 Thailand, and *see under* Thailand
 trade agreements, developing countries and 140
- ten Kate, K. 264
 terminator technologies 213
 test data *see* model law for protection of undisclosed data
 Thai Plant Variety Protection Act (1999) 243
Thai Rak Thai government 259
 Thailand
 collecting societies 30
 food and medicines 257
 GIs, and 283, 290
 international trade negotiations 166–7
 investment, foreign 150, 156–8, 166
 medicines, natural resources for 170
 pharmaceutical industry
 characteristics 149–51
 generic and branded drugs 152–4
 mid-level producer 148
 prices 154–6, 164, 166, 168
 TRIPS-Plus policies and 140–70
 PVP laws 242–6, 248–51, 259, 260, 265, 266
 research and development 158–61, 163–4, 258
 seed exchange networks 252
 sui generis systems *see* Asia *under* sui generis systems for plant variety protection
 traditional knowledge 261–3
 transfer of technology 162–3, 165–8
 US FTA 54, 140–46, 163–4
 non-transparent negotiations 142–3

- pharmaceutical inventions protection 143–6
 - compulsory licences 144–5, 160–61
 - data exclusivity 145
 - drug registration 145
 - investment 146, 156–8
 - patentability 144
 - patents 144, 145, 163–4
 - prices *see above*
 - trademarks 145, 166
- potential effects 140–42
- third party rights 399–400
- tie-ins 162–3
- trade 61
 - description 274, 288
 - international 5
 - investment frameworks (TIFAs), and 57–8
 - led investment 124
 - losses 37
 - negotiations 15
 - secrecy 10
- see also* China; free trade agreements
- Trade Description Act (1972), Malaysia 288
- Trade Mark Act (1999), India 285
- Trademark Act (1976), Malaysia 288
- Trademark Act (2001), China 284
- Trademark Law No. 15 of 2001, Indonesia 288
- Trademark Law Treaty 56, 145
- trademarks and trademark protection 294
 - Arab countries, in *see under* Arab countries
 - China, in *see under* China
 - IGOs, and 275–6
 - misuse *see* misuse
 - United States-Thailand FTA, and *see under* Thailand
- traditional knowledge 217–19, 221, 229
 - access and benefit sharing 254–5, 264
 - agriculture 241
 - customary knowledge and protocols 170, 264
 - Intergovernmental Committee 218
 - IP and, consumer groups discussing 63
 - medicines 170, 241
 - misappropriation, 60
 - plant varieties 251, 259
 - prior informed consent 255
 - protection and promotion 55, 235–7, 261–3
 - registries and databases 161–3, 164
 - research, and *see under* research and development
 - WIPO 217, 263, 264
- see also* education and access to knowledge
- transitional arrangements and periods 54, 98–9, 103
- transnational corporations (TNCs) 79, 142, 149, 154, 155, 156, 162, 169
- Treatment Action Campaign v Bristol-Myers Squibb* 193–4, 196
- Tregear, A. 294
- TRIPS Agreement (1994) xix, 51, 141, 311, 370
 - Arab countries, and *see under* Arab countries
 - Articles
 - 1 273, 319
 - 3 245
 - 7 99, 216, 319–20
 - 8 43, 99, 319–21, 364–5
 - 9 319–21
 - 13 12, 319, 321
 - 22 273, 282, 292
 - 23 273, 282, 292
 - 24 291
 - 27 43, 57, 220–22, 225–6, 235–7, 260, 283
 - 31 365, 393
 - 39 374, 375
 - 40 319, 321, 365
 - 41 46
 - 42 392
 - 44 390–91
 - 46 393
 - 63 322
 - 65 273
 - 69 25
 - 70 101
 - barriers not covered 46
 - Brazil, and 15
 - collecting societies 28, 30
 - community rights 225
 - competition law 364–7, 369
 - compliance 185, 245, 273
 - compliant 98–106, 112, 134–5, 181–2, 185, 225, 289, 324
 - confidentiality 345
 - data exclusivity, and, 7, 10–11, 15
 - database protection 9
 - dispute settlement US/China 37
 - enforcement *see under* enforcement
 - flexibilities 223, 227, 311, 365, 366–7
 - GIs *see under* indication of geographical origins (IGOs) and GIs
 - implementation 25, 53, 59
 - Indian Patents Act, and *see under* Indian Patents Act (1970)
 - IP review xxi–xxii
 - IPRs
 - data exclusivity 10–11
 - database protection 9
 - expanded description of exclusive rights in xx
 - sustainable development, and 210–13

- least developed countries, and 54
 non-discrimination, and 43, 226, 245
 objectives xxi
 obligations 28, 156, 279, 288, 289
 parallel imports and trade *see under* parallel
 imports and trade
 patents, and 156
 patentability, exclusion from 224
 pharmaceuticals 71, 156
 protection periods xx, 10, 165
 public health and *see under* public health
 protection
 sui generis protection of plant varieties
 236–7
 technical assistance 62, 368
 test data protection 370, 371, 374, 375,
 384
- TRIPS-Plus**
 agenda 15, 84
 Arab countries, and *see under* Arab
 countries
 bilateral agreements 292–3
 commitments 54, 140
 defined 54
 developing countries, and 54–5
 enforcement 390, 391, 395, 397–8, 400–401
 FTAs, and 54–5, 363
 EFTA 57
 IP review xxi–xxii
 IPRs, compulsory licences, and 12
 minimum standards, TRIPS 43, 105, 141,
 183, 319–20
 pharmaceuticals 71, 370, 371
 provisions 12, 58, 143, 145, 146, 164–6
 sub-Saharan countries, and *see* sub-Saharan
 African countries
 test data protection 370, 371
 Thailand pharmaceutical industry, and *see*
 under Thailand
- trade and investment frameworks 57–8
 tuberculosis 103, 177, 384
 malaria, and 118, 129, 153, 179
- Tunis Model Law on Copyright for Developing
 Countries 323–4
- Tunisia 56, 57
 Turkey 162
 turmeric 262, 285
 Twain, Mark 48–9
- Uganda 182, 223, 229–30, 314, 317–19
 Ukraine 57
 unfair competition 274, 288, 292, 370
- UNIDO 167
 unilateral measures 402
 United Arab Emirates 58
- United Kingdom 106, 150, 151, 274
 Commission on IPR *see* Commission on
 Intellectual Property Rights (CIPR)
 generics sales 116, 119
 pharmaceuticals 147, 148, 151
- United Nations
 Asian and Pacific Development Institution
 (UNAPDI) 153
 Centre on Transnational Corporation 162
 Conference on Trade and Development
 (UNCTAD) xx, 54, 167, 237, 245, 370
 Convention on Biological Diversity (CBD)
 xx, 26, 217, 223, 235, 239–40, 350
 Development Programme (UNDP) 182,
 185, 305, 306, 357
 Educational Scientific and Cultural
 Organization (UNESCO) xx, 26, 323
 Environment Programme (UNEP) 216
 Food and Agricultural Organization *see*
 Food and Agricultural Organization
 (FAO)
 Millennium Development Goals xxiii
- United States (US)
 administration 57, 118, 141
 anticircumvention provisions, DRM and
 13–14, 16, 313
 antitrust policy 364
 Bayh-Dole Law (1980) 344
 Bolar exemption 109–10
 Bureau of Alcohol, Tobacco and Firearms
 292
 China, relations and dispute with 37, 46,
 47
 compulsory licences 108
 Constitution 7
 copyright 13, 312
 counterfeiting and piracy losses 37
 database protection, IPRs and 8, 9
 Digital Millennium Copyright Act (1998)
 (DMCA) 13, 312
 Emergency Plan *see* President's Emergency
 Plan for AIDS Relief (PEPFAR)
 enforcement, and 390, 397, 399, 402
 Federal Drug Administration *see* Food and
 Drug Administration, US (FDA)
 Federal Food Drug and Cosmetics Act
 377
 Federal Trade Commission (FTC) 118
 Food and Drug Administration *see* Food
 and Drug Administration, US
 (FDA)
 FTAs xix, 141–2, 177, 242, 363, 370
 Arab countries 56, 57–9
 Australia 312, 366
 Bahrain 58, 63, 379

- Central American countries 53
 - Dominican Republic, and *see* CAFTA-DR
- developing countries, with 52
- Chile 379, 384
- DRM, and 13
- IPRs, and 5, 9
- Jordan 57, 58, 59, 379
- Korea 366
- Morocco 53, 58, 313, 382
- Oman 58, 379
- Peru 27, 36, 254, 384
- SACU 54, 311–13
- Singapore 12, 384
- Thailand 54, 140–46, 163–4
- Vietnam 290
- generic entry studies 72, 87–9
- generics sales 116–19, 120, 121–2
- GURTs, and 220
- harmonization approach 37
- health 108
- investment agreements 57–9, 150
- IP protection, improved 49
- licences 364
- Middle East Free Trade Area 57–8
- Pakistan IP decision-making, and 24
- Patent and Trademark Office, US (USPTO) 121
- patent law 108, 110
- patent protection of research tools 10–11
- pharmaceuticals 71, 147, 148, 151
- plan for AIDS Relief *see* President's Emergency Plan for AIDS Relief (PEPFAR)
- research personnel 159
- Section 301 Priority Watch List *see* Priority Watch List, Section 301
- technical assistance 368–9
- Trade Representative (USTR) 10, 38–9, 40, 47, 143–5, 311–13, 382, 399
- United States Agency for International Development (USAID) 26
- United States Drug Price Competition Act *see* Hatch-Waxman Act
- United States–Shrimp* [1998] 219
- universities 29, 126, 150, 158, 169, 310–11, 330, 337
 - IPR, and 341–50, 353, 357–8
- University of Costa Rica 346–7
- UPOV Convention 56, 57, 212, 216–18, 237–9, 253, 348
 - sui generis protection, as *see under* sui generis systems for plant variety protection
- Uruguay 36, 283
- Uruguay Round of Trade Negotiations 51, 97, 141, 167, 217, 273, 282–3, 292, 321, 363, 390
- use-restriction of a specific trait (T-GURTs) 214
- utility model protection 43–4
- utility models 24, 44, 344, 358, 396
- Uzbekistan 241
- Van Bay, N. 291
- Van Caenegem, W. 276
- variety-use restriction (V-GURTs) 214
- Venezuela 36
- Vernon, J.M. 87–8
- vertical licensing practices 364
- video compact discs (VCDs) 39
- Vietnam 39, 148, 150, 157, 241–2, 261, 290–91
- Vivas-Eugui, D. 54, 279
- voluntary licences *see under* Kenya; South Africa
- Wagle, S. 284, 288, 290, 291
- Ward, M.R. 88
- wars and civil conflict 29
- Watal, Jayashree 77–8, 273
- wild plant variety protection *see under* sui generis systems for plant variety protection
- wines and spirits 250, 273, 280–84, 289–90, 292
- World Bank 42
 - Institute (WBI) 370
- World Customs Union 390
- World Health Organization (WHO) xxi, 148, 149, 151, 175, 182
 - Intergovernmental Working Group on Public Health (IGWG) xxi
- see also* medicines and drugs; public health protection
- World Intellectual Property Organization (WIPO) xx, xxi–xxii, 26
 - benefit sharing 239
 - collecting societies 29
 - Copyright Treaty (1996) 13, 311, 321
 - Development Agenda *see* Development Agenda
 - development dimensions 63
 - Diplomatic Convention xxxiii, 9, 14
 - enforcement, and 390
 - history and role 216–17
 - IGC on Intellectual Property and Genetic Resources 217
 - IP, and xxi–xxiii, 311, 363, 368

- negotiations and debates 62–3, 167
- Performances and Phonograms Treaty (1996) 13
- role and IP standard setting 52, 56
- soft law, and 52
- Standing Committee on Copyright and Related Rights 9
- technical assistance *see under* technical assistance
- trademarks 56, 145
- traditional knowledge, and *see under* traditional knowledge
- TRIPS Plus 55
- World Trade Organization (WTO) xix, xx, xxi, 219, 311
 - accession to 39–40, 54, 55, 56, 370
 - Agreement on Trade-Related Aspects of Intellectual Property *see* TRIPS
 - disputes settlement *see under* dispute settlement
 - enforcement *see* TRIPS *under* enforcement
 - General Council 30 August decision *see under* sub-Saharan African countries
 - multilateral negotiations 140, 141, 166–7
 - Secretariat 274, 275, 276, 277, 279, 296
 - sui generis* systems 244–5
- Wu, T. 47
- Xiaoping, Deng 38
- Yu, Peter K. 39, 41, 44, 46, 48
- Zambia
 - books 308
 - COMESA 197
 - compulsory licensing *see under* compulsory licences and licensing
 - Doha Declaration, and 185, 186, 187
 - education, and *see* education and access to knowledge *under* southern Africa
 - government use provisions 185, 186–7
 - HIV/AIDS in 185
 - least developed country, as 185
 - Patents Act 186, 187, 200
 - patents, duration of 186
 - WTO General Council 30 August decision implementation 176, 185–7
- Zimbabwe 185

